MV BioTherapeutics

Existing treatments for gastrointestinal immune disorders often rely on immunosuppressive therapies, which often lead to serious side effects. MV BioTherapeutics, a spin-off of the Institute for Research in Biomedicine (IRB), is addressing this medical need with a novel, proprietary enzyme delivery platform for extracellular ATP modulation in the gut. The approach offers a focus and targeted treatment for inflammatory bowel diseases (IBD), chronic conditions like Crohn’s disease and ulcerative colitis that cause long-term inflammation of the digestive tract. In contrast to existing solutions, the treatment is highly localised and based on restoring immune balance rather than suppressing it.